On June 22, Moderna declined 5.34% in regular trading, trading at $60.915/share, with turnover of $88.77 million. The pullback follows a six-session rally of 39% that had pushed the stock to its highest level since September of the prior year.

On the news front, Leerink Partners raised its price target on Moderna from $21 to $24 but maintained its underperform rating, signaling continued skepticism despite the recent run-up. According to analyst consensus polled by FactSet, Moderna carries an average hold rating with a mean price target of $47.05. Multiple prior catalysts — including the FDA advisory committee's unanimous 9-0 vote recommending approval of the company's mRNA-based seasonal influenza vaccine for adults 50 and older, and plans to potentially expand manufacturing capacity in Germany by acquiring facilities from BioNTech — appear to have been fully priced in. With the FDA's final approval decision on mRNA-1010 not expected until early August, short-term profit-taking pressure has emerged as the market enters a news vacuum period.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)